Quarterly ResultMay 7, 2026, 04:35 PM
Amneal Q1 Net Income $62.26M, EPS $0.19; Revenue $722.52M
AI Summary
Amneal Pharmaceuticals reported a significant increase in its first-quarter 2026 financial results, with net income attributable to the company soaring to $62.26 million and diluted EPS reaching $0.19. Net revenue also saw a modest increase to $722.52 million. The company recognized a $6.9 million gain from a change in its Pfizer collaboration agreement and successfully repriced its Term Loan, reducing interest rate margins. However, net cash used in operating activities was $26.74 million for the quarter.
Key Highlights
- Net income attributable to Amneal Pharmaceuticals surged 410.5% to $62.26 million.
- Diluted earnings per share increased 375% to $0.19.
- Net revenue rose 3.9% to $722.52 million.
- Recognized a $6.9 million gain from the Pfizer collaboration agreement change.
- Repricing amendment reduced Term Loan Due 2032 interest rate margins by 50 basis points.
- Affordable Medicines segment revenue increased to $423.24 million.
- Specialty segment revenue grew to $133.27 million.
- Net cash used in operating activities was $26.74 million.
Price Impact
More from AMRX